Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by sah1on Oct 30, 2020 1:03pm
139 Views
Post# 31813700

RE:Hi sah1

RE:Hi sah1

Well TV's greed is on full display again. Under their management and inability to meet milestones, retail has had to suffer another massive dilution.

The simplest and fairest thing for TV  to do was to just increase the LoC in September given their poor management of the company since the restructuring.

Alternatively, a loan could have been offered complete with warrants at $5.50. But no, TV does a private equity offering with warrants which no doubt will be exercised following Ryplazim approval. So close to a 50% dilution when the dust has settled. 

Interesting that the cash burn was only $6M in September. With $36M in the bank as of September 30th or cash runway to the end of March 2021,  why did the company have to do the financing at this juncture? This will look particularly bad if FDA grants early approval of Ryplazim, which is always a possibility.

I would like to know if Consonance is still in the picture? I wouldn't be surprised if it was behind the  big sell off over the last couple of weeks. It will be interesting to see the SEC disclosure next week.

I am not a happy camper.

<< Previous
Bullboard Posts
Next >>